Skyclarys (omaveloxolone) — Highmark

Initial criteria

• age ≥ 16 years
• Prescribed by or in consultation with a neurologist or a provider who specializes in the treatment of Friedreich’s ataxia (FA)
• Diagnosis of Friedreich’s ataxia (FA), confirmed by genetic testing (FXN gene mutation)

Reauthorization criteria

• Prescriber attests that the member has experienced positive clinical response to therapy

Approval duration

12 months